查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010924

性与生殖健康药品市场：2026-2032年全球市场预测（依药物类别、作用机制、处方状态、给药途径、通路及最终用户划分）

Sexual & Reproductive Health Drugs Market by Drug Class, Mechanism Of Action, Prescription Status, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，性与生殖健康相关药物的市场价值将达到 407.2 亿美元，到 2026 年将成长到 460 亿美元，到 2032 年将达到 1,002.6 亿美元，复合年增长率为 13.73%。

主要市场统计数据
基准年 2025 407.2亿美元
预计年份：2026年 460亿美元
预测年份 2032 1002.6亿美元
复合年增长率 (%) 13.73%

对塑造性与生殖健康治疗市场的现代驱动因素、临床创新和不断变化的患者期​​望进行了权威概述。

性与生殖健康（SRH）治疗领域正处于一个十字路口，临床创新、不断变化的监管环境以及患者期望的转变是三大因素交汇之处。避孕技术的进步、爱滋病预防策略的拓展、生育治疗和荷尔蒙补充疗法的进步，以及数位化医疗解决方案和不断演进的报销模式，都使得策略规划的明确变得尤为迫切。为此，从製药公司到保险公司和医疗保健系统等相关人员都在重新评估产品系列、经销伙伴以及循证研究的优先事项，以使其与以患者为中心的护理路径保持一致。

技术创新、不断变化的法规和患者行为的改变如何汇聚在一起，重塑产品开发、获取途径和商业策略。

性与生殖健康药物领域正经历多重变革，这些变革正在重新定义产品价值和相关人员的参与方式。从植入式避孕药、长效注射剂到经皮系统，药物传递技术的创新日益重视药物的持久性、便利性和用药依从性。同时，数位健康平台和远端医疗的发展使得远距处方、线上咨询和用药依从性监测成为可能，降低了传统的用药门槛，并催生了新的分销模式。

评估美国于 2025 年征收关税对供应链、采购和临床连续性造成的广泛影响。

美国2025年实施的关税对性与生殖健康（SRH）疗法的供应链、筹资策略和定价结构产生了即时的连锁反应。依赖跨国采购活性成分、包装材料和给药装置的製造商被迫重新思考筹资策略，以缓解利润率压力。因此，一些公司加快了供应商多元化进程，并将製造地分散在各地，以保护生产免受关税波动的影响，并确保患者护理的连续性。

详细的細項分析，将药物类别、给药途径和分销管道特征与临床、监管和商业性优先事项相匹配。

精准理解药物细分对于应对不同药物类别、作用机制和给药途径带来的治疗和商业性复杂性至关重要。检验不同药物类别之间的差异，可以揭示其研发和商业化动态的差异。避孕药包括植入式避孕药、注射式避孕药、子宫内避孕系统、口服避孕药和经皮吸收贴片。即使是口服避孕药，不同的剂型——胶囊、粉末和药片——也会影响患者的用药依从性和生产过程的选择。不孕症治疗药物分为促性腺激素释放激素类似物、促性腺激素分泌和促排卵药，每种药物都有其自身的临床给药和监测需求。用于HIV预防的抗逆转录病毒药物，特别是含有恩曲他滨和替诺福韦的方案，与持续预防策略密切相关，并与公共卫生计画相辅相成。同时，荷尔蒙疗法分为雌激素途径和黄体素途径，其适应症包括替代疗法和避孕。

区域比较分析突显了主要全球市场的监管复杂性、分销现实和病患行为模式。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势差异显着，每个地区都有其独特的监管环境、病患行为和分销基础设施，这些都会对策略产生重大影响。在美洲，整合式医疗模式的高普及率和成熟的私人保险市场支持了差异化给药系统的快速发展，而公共卫生计画则推动了爱滋病预防抗逆转录病毒药物和计划生育倡议的规模化应用。跨境贸易关係和多元化的支付方结构要求制定弹性价格设定和市场准入计划。

深入了解领先的研发公司如何调整其产品组合创新、製造伙伴关係和证据策略，以确保临床和商业性优势。

在性与生殖健康治疗领域，企业策略日益注重产品组合的广度、实证实践的敏捷性以及成熟的伙伴关係。主要企业正努力平衡对长效给药平台（如植入和注射剂）的投资与对新一代口服和经皮製剂的投资，以满足不同患者的偏好。为了支持这些创新，企业正在改进临床试验设计，引入可操作的终点指标，并纳入患者报告结局指标（PRO），以简化报销谈判并展现产品在现实世界中的价值。

为高阶主管提供切实可行的建议，以加强供应链、证据产生和全通路分销，从而加快招聘速度并保持市场准入。

产业领导者应采取整合式方法，将临床创新与稳健的供应链和以客户为中心的配送策略结合。优先考虑来源多元化和扩大区域製造能力，以降低关税和地缘政治风险，同时投资于品管系统并与供应商建立良好关係，以确保产品完整性。在考虑供应侧的同时，加快证据产生项目，纳入真实世界数据和病患报告结果，以支持报销谈判并在不同的支付方环境中展现价值。

严谨的混合方法研究框架，结合对关键相关人员的访谈、监管分析和资料检验，为可操作的见解提供了支持。

本分析的调查方法结合了定性访谈、监管指南的系统性回顾以及与专有临床和商业资料集的三角验证，以确保获得稳健且多角度的洞见。主要研究包括对临床医生、供应链经理、支付方和药房经理进行结构化检验，以了解实际运作和不断变化的需求。这些洞见与对监管趋势、核准途径和上市后监测要求的全面回顾相结合，以评估政策变化如何影响临床实践。

策略结论强调，要维持成长，需要证据一致性、供应链韧性和以病人为中心的商业化。

总之，性与生殖健康治疗领域的特点是技术快速发展、监管预期不断变化以及患者需求波动，这些因素共同带来了机会和挑战。对长效给药系统、多样化的口服和经皮製剂以及数位化用药依从性工具的日益依赖，正在重新定义治疗的价值提案。同时，贸易趋势和区域监管差异要求建立具有韧性的供应链和灵活的打入市场策略，以确保患者能够获得治疗并维持商业性可行性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 性与生殖健康药品市场：依药物类别划分

  • 避孕药
    • 植入式避孕器
    • 注射式避孕药
    • 子宫内避孕系统
    • 口服避孕药
    • 经皮贴剂
  • 治疗勃起功能障碍的药物
  • 不孕症药物
    • GnRH类似物
    • 促性腺激素
    • 促排卵药物
  • 用于预防爱滋病毒感染的抗逆转录病毒药物
  • 荷尔蒙疗法

第九章 依作用机转分類的性与生殖健康相关药物市场

  • 荷尔蒙系统
  • 非荷尔蒙类

第十章：依处方状态分類的性与生殖健康相关药物市场

  • 非处方药
  • 处方笺

第十一章 性与生殖健康药品市场：依给药途径划分

  • 注射药物
  • 口服
    • 胶囊
    • 粉末
    • 药片
  • 外用
  • 经皮吸收

第十二章 性与生殖健康药品市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 性与生殖健康药品市场：依最终用户划分

  • 诊所
  • 居家照护
  • 医院

第十四章 性与生殖健康药品市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 性与生殖健康药品市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 性与生殖健康药品市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国性与生殖健康药品市场

第十八章：中国性与生殖健康相关药物市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cipla EU Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Lupin Limited
  • Mayne Pharma Group Limited
  • Merck & Co., Inc.
  • Mithra Pharmaceuticals SA
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theramex HQ UK Limited
  • Viatris Inc.
Product Code: MRR-434CCDA0523A

The Sexual & Reproductive Health Drugs Market was valued at USD 40.72 billion in 2025 and is projected to grow to USD 46.00 billion in 2026, with a CAGR of 13.73%, reaching USD 100.26 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 40.72 billion
Estimated Year [2026] USD 46.00 billion
Forecast Year [2032] USD 100.26 billion
CAGR (%) 13.73%

An authoritative introduction to contemporary drivers, clinical innovations, and evolving patient expectations shaping sexual and reproductive health therapeutics

The sexual and reproductive health therapeutics landscape sits at a crossroads of clinical innovation, regulatory evolution, and shifting patient expectations. Advances in contraceptive technologies, extended HIV prevention strategies, fertility interventions, and hormone replacement protocols are converging with digital health solutions and evolving reimbursement models to create renewed urgency for strategic clarity. In response, stakeholders from manufacturers to payers and health systems are re-evaluating product portfolios, distribution partnerships, and evidence generation priorities to align with patient-centered care pathways.

At the same time, demographic shifts and changing patterns of sexual behavior are reshaping demand profiles across population segments. Younger cohorts demonstrate rising interest in user-controlled methods and discreet delivery systems, while aging populations heighten demand for hormonal therapies and fertility care. Consequently, investment in formulation diversity, adherence-support technologies, and safety monitoring is becoming central to maintaining clinical relevance and competitive differentiation. This introduction sets the stage for a deeper examination of transformative shifts, trade policy impacts, segmentation nuance, regional dynamics, company strategies, and pragmatic recommendations for leaders navigating the next phase of market evolution.

How technological innovation, regulatory evolution, and shifting patient behaviors are converging to reshape product development, access, and commercial strategies

The landscape for sexual and reproductive health therapeutics is undergoing multiple, simultaneous transformations that are redefining product value and stakeholder engagement. Technological innovations in drug delivery-ranging from implantable contraceptives and long-acting injectables to transdermal systems-are increasing the emphasis on durability, convenience, and adherence. Meanwhile, the growth of digital health platforms and telemedicine is enabling remote prescribing, virtual counseling, and adherence monitoring, thereby reducing traditional access barriers and enabling new distribution models.

Regulatory trajectories are also shifting, with adaptive pathways and accelerated review mechanisms becoming more prevalent in response to unmet clinical needs. This regulatory agility is encouraging earlier lifecycle investments and closer dialogue between developers and authorities. Additionally, the integration of real-world evidence and patient-reported outcomes into regulatory dossiers is elevating the importance of post-market surveillance and continuous quality improvement. Commercially, value-based contracting and outcomes-linked pricing are gaining traction, prompting manufacturers to align clinical endpoints with payer expectations and patient-centered measures.

Finally, social and demographic forces-such as increasing contraceptive autonomy, expanded HIV prevention awareness, and the normalization of fertility interventions-are reshaping demand composition. As a result, organizations that can combine clinical differentiation with flexible distribution strategies and robust evidence programs will be best positioned to capture long-term relevance in this evolving market.

Assessing the wide-ranging supply chain, procurement, and clinical continuity effects stemming from the United States tariffs introduced in 2025

The introduction of United States tariffs in 2025 has created immediate and cascading effects across supply chains, procurement strategies, and pricing architecture for sexual and reproductive health therapeutics. Manufacturers that rely on cross-border inputs for active pharmaceutical ingredients, packaging components, and delivery devices have had to reassess sourcing strategies to mitigate margin pressure. Consequently, several firms accelerated supplier diversification and regionalized manufacturing footprints to insulate production against tariff volatility and to maintain continuity of care for patients.

Trade measures also influenced procurement decisions at the distributor and payer levels, prompting a re-evaluation of tender timelines and contractual terms to reflect increased input cost uncertainty. In certain cases, downstream stakeholders deferred non-essential pipeline launches or prioritized products with domestic supply chains to avoid exposure to tariff pass-through. From a clinical operations perspective, the tariffs have prompted more intensive scenario planning for inventory buffers and contingency distribution routes, particularly for injectable therapies and specialty contraceptives that require cold chain or specific handling.

In parallel, the tariffs accelerated strategic conversations about onshore capacity investment and public-private partnerships to secure manufacturing resilience. Policymakers responded by engaging with industry to identify critical medicines and components warranting expedited permitting or tariff relief, while manufacturers intensified bilateral negotiations with suppliers to manage lead times and cost escalation. Overall, the tariff environment in 2025 underscored the strategic imperative of supply chain transparency, flexible sourcing, and active engagement with procurement stakeholders to preserve patient access and commercial stability.

Deep segmentation intelligence that aligns drug class nuances, administration routes, and channel distinctions to clinical, regulatory, and commercial priorities

A nuanced understanding of segmentation is essential to navigate the therapeutic and commercial complexity across drug classes, mechanisms, and access pathways. Examining drug class distinctions reveals divergent development and commercialization dynamics: contraceptives encompass implantable contraceptives, injectable contraceptives, intrauterine systems, oral contraceptives, and transdermal patches; within oral contraceptives, formulation variation across capsules, powders, and tablets shapes adherence and manufacturing choices. Fertility therapies are distinguished by GnRH analogues, gonadotropins, and ovulation inducers, each with unique clinical administration and monitoring requirements. HIV prevention antiretrovirals, notably regimens including emtricitabine and tenofovir, involve sustained prophylactic strategies that intersect with public health programming, while hormonal therapies split into estrogen and progesterone pathways that serve both replacement and contraceptive indications.

Mechanism of action segmentation between hormonal and non-hormonal agents informs safety, side-effect profiles, and patient counseling, which in turn affects prescribing patterns and formulary placement. Prescription status-differentiating over-the-counter availability from prescription-only products-shapes point-of-care interactions, consumer education needs, and private-label opportunities. Route of administration considerations, spanning injectable, oral, topical, and transdermal modes with oral forms further differentiated by capsules, powders, and tablets, determine cold chain requirements, adherence considerations, and device compatibility. Distribution channel segmentation across hospital pharmacy, online pharmacy, and retail pharmacy, with retail further split into chain and independent outlets, highlights divergent margin structures, promotional strategies, and partnership models. Finally, end user segmentation including clinics, home care, and hospitals, with hospitals categorized as private and public, underscores differing procurement rules, treatment protocols, and reimbursement pathways. Taken together, these segmentation lenses allow stakeholders to prioritize clinical development, optimize channel strategies, and design evidence generation that aligns with both payer expectations and patient preferences.

Comparative regional intelligence highlighting regulatory complexity, distribution realities, and patient behavior patterns across major global markets

Regional dynamics vary markedly across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region presenting distinct regulatory landscapes, patient behaviors, and distribution infrastructures that materially influence strategy. In the Americas, high adoption of integrated care models and mature private pay markets support rapid uptake of differentiated delivery systems, while public health programs drive scale for HIV prevention antiretrovirals and family planning initiatives. Cross-border trade relationships and heterogenous payer mixes require adaptable pricing and market access plans.

Europe, Middle East & Africa presents a complex mosaic of regulatory harmonization efforts alongside significant variability in procurement capabilities. In many markets, centralized reimbursement decision-making and strong public sector purchasing channels favor therapies with robust health economic evidence, whereas emerging economies within the region signal demand for cost-effective, easy-to-administer solutions. Asia-Pacific demonstrates a bifurcated picture: advanced economies accelerate adoption of digitally enabled adherence tools and long-acting therapeutics, while other markets prioritize manufacturing localization, affordability, and scalable distribution through retail and hospital networks. Across all regions, culturally informed patient engagement and nuanced regulatory navigation remain prerequisites for successful market entry and sustained uptake.

Insights into how leading developers are aligning portfolio innovation, manufacturing partnerships, and evidence strategies to secure clinical and commercial advantage

Company strategies in the sexual and reproductive health therapeutics space are increasingly defined by portfolio breadth, evidence generation agility, and partnership sophistication. Leading developers are balancing investments in long-acting delivery platforms-such as implants and injectables-with next-generation oral and transdermal formulations to appeal to diverse patient preferences. To support these innovations, firms are strengthening clinical trial design with pragmatic endpoints and incorporating patient-reported outcome measures to facilitate reimbursement discussions and to demonstrate real-world value.

Strategic alliances with contract manufacturing organizations and specialized device manufacturers are becoming more common as companies seek to de-risk complex formulation launches and to accelerate time-to-market. Commercially, firms are diversifying distribution strategies to include direct-to-consumer channels, partnerships with online pharmacies, and tailored programs for clinic networks, thereby expanding reach while preserving professional oversight where clinically required. Additionally, companies are investing in post-market surveillance infrastructure and pharmacovigilance capabilities to sustain trust and comply with evolving regulatory expectations. Those that combine manufacturing resilience, evidence-led commercialization, and nimble partnership models will be best placed to capture long-term clinical and commercial relevance.

Actionable recommendations for executives to fortify supply chains, evidence generation, and omnichannel distribution to accelerate adoption and preserve access

Industry leaders should pursue an integrated approach that aligns clinical innovation with resilient supply chains and customer-centric distribution strategies. Prioritize diversification of sourcing and expansion of regional manufacturing capacity to mitigate tariff and geopolitical risks, while simultaneously investing in quality management systems and supplier relationships to preserve product integrity. Parallel to supply considerations, accelerate evidence-generation programs that incorporate real-world outcomes and patient-reported measures to support reimbursement negotiations and to demonstrate value across diverse payer environments.

From a commercial perspective, develop omnichannel distribution models that blend clinic-based prescribing with online pharmacy access and targeted retail partnerships, ensuring appropriate clinical oversight for prescription-dependent therapies while expanding convenience for over-the-counter options. Embrace digital tools for adherence support, remote counseling, and pharmacovigilance to enhance patient outcomes and to gather meaningful post-launch data. Finally, pursue collaborative engagements with public health programs and payers to align product introductions with population health priorities, thereby enhancing access and creating scalable pathways for broader uptake. These coordinated actions will strengthen market resilience and accelerate adoption of clinically differentiated therapies.

A rigorous mixed-methods research framework combining primary stakeholder interviews, regulatory analysis, and data triangulation to underpin actionable findings

The research methodology underpinning this analysis combined primary qualitative interviews, systematic review of regulatory guidance, and triangulation with proprietary clinical and commercial datasets to ensure robust, multi-perspective insights. Primary research included structured interviews with clinicians, supply chain managers, payers, and pharmacy directors to capture operational realities and evolving preferences. These insights were synthesized with a comprehensive review of regulatory trends, approval pathways, and post-market surveillance requirements to assess how policy shifts interact with clinical practice.

Data triangulation involved cross-referencing public regulatory filings, clinical trial registries, and distribution channel intelligence to validate thematic findings. The approach prioritized transparency in assumptions and rigorous documentation of source provenance. Where relevant, scenario planning exercises were employed to explore the operational implications of supply chain disruptions and policy shifts, and sensitivity analyses were conducted to test the robustness of strategic recommendations under alternative market conditions. This mixed-methods framework supports actionable conclusions that are grounded in both frontline experience and documented regulatory and clinical science.

Strategic conclusions emphasizing the need for evidence alignment, supply chain resilience, and patient-centric commercialization to sustain growth

In conclusion, the sexual and reproductive health therapeutics landscape is characterized by rapid technological progress, evolving regulatory expectations, and shifting patient demand that together create both opportunity and complexity. Long-acting delivery systems, diversified oral and transdermal formulations, and increased reliance on digital adherence tools are redefining therapeutic value propositions. Concurrently, trade dynamics and regional regulatory variation necessitate resilient supply chains and adaptive market access strategies to preserve patient access and commercial viability.

Stakeholders that invest in evidence generation aligned with payer needs, build flexible manufacturing and distribution networks, and deploy patient-centric commercial models will be best positioned to sustain growth and clinical impact. As the landscape continues to evolve, continuous engagement with clinical, regulatory, and supply chain partners will be essential to translate innovation into meaningful patient outcomes while managing operational risk. The insights presented here offer a strategic foundation for organizations seeking to navigate near-term disruptions and to capitalize on long-term opportunities within this critical therapeutic area.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sexual & Reproductive Health Drugs Market, by Drug Class

  • 8.1. Contraceptives
    • 8.1.1. Implantable Contraceptives
    • 8.1.2. Injectable Contraceptives
    • 8.1.3. Intrauterine System
    • 8.1.4. Oral Contraceptives
    • 8.1.5. Transdermal Patches
  • 8.2. Erectile Dysfunction Treatments
  • 8.3. Fertility Drugs
    • 8.3.1. GnRH Analogues
    • 8.3.2. Gonadotropins
    • 8.3.3. Ovulation Inducers
  • 8.4. HIV Prevention Antiretrovirals
  • 8.5. Hormonal Therapies

9. Sexual & Reproductive Health Drugs Market, by Mechanism Of Action

  • 9.1. Hormonal
  • 9.2. Non Hormonal

10. Sexual & Reproductive Health Drugs Market, by Prescription Status

  • 10.1. Over The Counter
  • 10.2. Prescription

11. Sexual & Reproductive Health Drugs Market, by Route Of Administration

  • 11.1. Injectable
  • 11.2. Oral
    • 11.2.1. Capsules
    • 11.2.2. Powders
    • 11.2.3. Tablets
  • 11.3. Topical
  • 11.4. Transdermal

12. Sexual & Reproductive Health Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Sexual & Reproductive Health Drugs Market, by End User

  • 13.1. Clinics
  • 13.2. Home Care
  • 13.3. Hospitals

14. Sexual & Reproductive Health Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Sexual & Reproductive Health Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Sexual & Reproductive Health Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Sexual & Reproductive Health Drugs Market

18. China Sexual & Reproductive Health Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amneal Pharmaceuticals, Inc.
  • 19.7. Aurobindo Pharma Limited
  • 19.8. Bayer AG
  • 19.9. Cipla EU Limited
  • 19.10. Cipla Limited
  • 19.11. Dr. Reddy's Laboratories Ltd.
  • 19.12. GlaxoSmithKline plc
  • 19.13. Hikma Pharmaceuticals PLC
  • 19.14. Johnson & Johnson
  • 19.15. Lupin Limited
  • 19.16. Mayne Pharma Group Limited
  • 19.17. Merck & Co., Inc.
  • 19.18. Mithra Pharmaceuticals SA
  • 19.19. Novartis AG
  • 19.20. Pfizer Inc.
  • 19.21. Sun Pharmaceutical Industries Ltd.
  • 19.22. Teva Pharmaceutical Industries Ltd.
  • 19.23. Theramex HQ UK Limited
  • 19.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 196. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 198. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 201. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 226. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 228. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 231. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 236. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 237. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 238. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 241. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)